

# Avner Shemer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11743880/publications.pdf>

Version: 2024-02-01

68  
papers

4,971  
citations

172457

29  
h-index

110387

64  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4689  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 130, 1344-1354.	2.9	731
2	IL-22“producing” T22“T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17“producing TH17 T cells. Journal of Allergy and Clinical Immunology, 2009, 123, 1244-1252.e2.	2.9	547
3	Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2013, 132, 361-370.	2.9	402
4	Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. Journal of Allergy and Clinical Immunology, 2011, 127, 954-964.e4.	2.9	375
5	Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. Journal of Allergy and Clinical Immunology, 2009, 124, 1235-1244.e58.	2.9	231
6	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. Journal of Allergy and Clinical Immunology, 2014, 134, 362-372.	2.9	224
7	Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. Journal of Allergy and Clinical Immunology, 2015, 136, 104-115.e7.	2.9	183
8	Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. Journal of Allergy and Clinical Immunology, 2011, 128, 583-593.e4.	2.9	182
9	Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. Journal of Allergy and Clinical Immunology, 2015, 136, 1277-1287.	2.9	176
10	Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets. Journal of Allergy and Clinical Immunology, 2015, 136, 941-951.e3.	2.9	175
11	An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. Journal of Investigative Dermatology, 2017, 137, 603-613.	0.7	156
12	Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal of Allergy and Clinical Immunology, 2014, 133, 1626-1634.	2.9	146
13	Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer. Journal of Allergy and Clinical Immunology, 2016, 137, 1091-1102.e7.	2.9	126
14	Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. Journal of Allergy and Clinical Immunology, 2016, 137, 118-129.e5.	2.9	96
15	Diabetic dermopathy and internal complications in diabetes mellitus. International Journal of Dermatology, 1998, 37, 113-115.	1.0	85
16	Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. Journal of Allergy and Clinical Immunology, 2015, 136, 208-211.	2.9	69
17	Autoimmune Disease Induction in a Healthy Human Organ: A Humanized Mouse Model of Alopecia Areata. Journal of Investigative Dermatology, 2013, 133, 844-847.	0.7	65
18	Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Experimental Dermatology, 2016, 25, 282-286.	2.9	62

#	ARTICLE	IF	CITATIONS
19	Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 712-720.	2.9	55
20	The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. <i>Journal of Dermatological Science</i> , 2015, 77, 74-76.	1.9	50
21	Update: medical treatment of onychomycosis. <i>Dermatologic Therapy</i> , 2012, 25, 582-593.	1.7	44
22	Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 498-501.e3.	2.9	39
23	Global perspectives for the management of onychomycosis. <i>International Journal of Dermatology</i> , 2019, 58, 1118-1129.	1.0	39
24	Common nail disorders. <i>Clinics in Dermatology</i> , 2013, 31, 578-586.	1.6	36
25	Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. <i>International Journal of Dermatology</i> , 2000, 39, 532-534.	1.0	35
26	Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0148450.	2.5	33
27	Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2030-2040.	0.7	33
28	Emollient foam in topical drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 799-807.	5.0	32
29	High prevalence of mixed infections in global onychomycosis. <i>PLoS ONE</i> , 2020, 15, e0239648.	2.5	32
30	The Hyper-IgE Syndrome. Two cases and review of the literature. <i>International Journal of Dermatology</i> , 2001, 40, 622-628.	1.0	31
31	Onychomycosis in Israel: epidemiological aspects. <i>Mycoses</i> , 2015, 58, 133-139.	4.0	29
32	Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 305-308.e6.	2.9	29
33	Iontophoretic Terbinafine HCL 1.0% Delivery Across Porcine and Human Nails. <i>Mycopathologia</i> , 2010, 169, 343-349.	3.1	27
34	Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 577-579.	2.9	27
35	Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2088-2091.	0.7	27
36	Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. <i>International Journal of Dermatology</i> , 1997, 36, 67-69.	1.0	26

#	ARTICLE	IF	CITATIONS
37	Wells' syndrome: report of a case and review of the literature. International Journal of Dermatology, 2001, 40, 148-152.	1.0	24
38	Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results. Journal of the American Academy of Dermatology, 2016, 74, 1251-1252.	1.2	23
39	Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Israel Medical Association Journal, 2008, 10, 417-8.	0.1	22
40	Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. Mycopathologia, 2016, 181, 851-856.	3.1	21
41	Ciclopirox nail lacquer for the treatment of onychomycosis: An open non-comparative study. Journal of Dermatology, 2010, 37, 137-139.	1.2	20
42	Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. Journal of Allergy and Clinical Immunology, 2014, 134, 955-957.	2.9	20
43	Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatologic Therapy, 2017, 30, e12545.	1.7	19
44	Comparative study of nail sampling techniques in onychomycosis. Journal of Dermatology, 2009, 36, 410-414.	1.2	17
45	Therapie der Tinea capitis " Griseofulvin versus Fluconazol " eine vergleichende Studie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 737-742.	0.8	16
46	Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Experimental Dermatology, 2019, 28, 35-44.	2.9	15
47	Onychomycosis in psoriatic patients - rationalization of systemic treatment. Mycoses, 2009, 53, 340-3.	4.0	14
48	Onychomycosis: rationalization of topical treatment. Israel Medical Association Journal, 2008, 10, 415-6.	0.1	14
49	Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail. JDDG - Journal of the German Society of Dermatology, 2007, 5, 1108-1111.	0.8	13
50	Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. Experimental Dermatology, 2017, 26, 272-275.	2.9	11
51	Treatment of tinea capitis " griseofulvin versus fluconazole " a comparative study. JDDG - Journal of the German Society of Dermatology, 2013, 11, 737-741.	0.8	9
52	Variability in Systemic Treatment Efficacy for Onychomycosis: Information That Clinical Studies Do Not Impart to the Office Dermatologist. Skin Appendage Disorders, 2018, 4, 141-144.	1.0	8
53	Griseofulvin and Fluconazole Reduce Transmission of Tinea Capitis in Schoolchildren. Pediatric Dermatology, 2015, 32, 696-700.	0.9	6
54	Once Weekly Application of Urea 40% and Bifonazole 1% Leads to Earlier Nail Removal in Onychomycosis. Skin Appendage Disorders, 2020, 6, 304-308.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis. Journal of Dermatological Treatment, 2021, 32, 310-313.	2.2	6
56	Fungal Infections (Onychomycosis, Tinea Pedis, Tinea Cruris, Tinea Capitis, Tinea Manuum, Tinea) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Analyses. , 2018, , 235-242.		5
57	Management of tinea capitis in Israel: A comparative study. Pediatric Dermatology, 2021, 38, 806-811.	0.9	5
58	A Retrospective Study Comparing K101 Nail Solution as a Monotherapy and in Combination with Oral Terbinafine or Itraconazole for the Treatment of Toenail Onychomycosis. Skin Appendage Disorders, 2018, 4, 166-170.	1.0	4
59	Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study. Dermatology, 2021, 237, 902-906.	2.1	4
60	Low-dose isotretinoin versus minocycline in the treatment of rosacea. Dermatologic Therapy, 2021, 34, e14986.	1.7	4
61	Betamethasone valerate foam: a look at the clinical data. Clinical Investigation, 2014, 4, 259-267.	0.0	2
62	Painful Nail. , 2018, , 287-301.		2
63	Wells' syndrome: report of a case and review of the literature. International Journal of Dermatology, 2001, 40, 148-152.	1.0	2
64	Onychomycosis: a simpler in-office technique for sampling specimens. Journal of Family Practice, 2012, 61, 552-4.	0.2	2
65	Cold subatmospheric and atmospheric pressure plasma for the treatment of Trichophyton rubrum onychomycosis: An in vitro study. Dermatologic Therapy, 2020, 33, e14084.	1.7	1
66	Diagnostic approach to tinea capitis with kerion: A retrospective study. Pediatric Dermatology, 2022, 39, 708-712.	0.9	1
67	Nagelproben bei Onychomykose:Vergleichsstudie mit einer Kurettage an drei Stellen des infizierten Nagels. JDDG - Journal of the German Society of Dermatology, 2007, 5, no.	0.8	0
68	Clinical significance of Candida isolation from dystrophic fingernails. Mycoses, 2020, 63, 964-969.	4.0	0